Allergy Therapeutics Share Discussion Threads

[raleigh43] 21/10/2022 16:15

Who are all the major shareholders now?

[raleigh43] 21/10/2022 10:28

Great news. Says Sky Capital.
A vote of confidence.

[wizzkid211] 20/10/2022 08:08

Resulting situation
on the date
on which threshold
was crossed
or reached 25.58% - 25.58% 173,740,037
------------------ --------------------- -------------- --------------------
Position of 22.02% -
previous notification
(if
applicab

[wizzkid211] 17/10/2022 15:04

RNS Number : 1398D

Allergy Therapeutics PLC

17 October 2022

Allergy Therapeutics plc

("Allergy Therapeutics", "ATL", the "Company" or the "Group")

Result of GM

17 October 2022 Allergy Therapeutics (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy immunotherapy, announces that at the General Meeting ("GM") held today all resolutions were duly passed.

Accordingly, the Company has conditionally raised total gross proceeds of approximately GBP17,000,000 million in aggregate (before expenses) through the Subscription and Debt Financing as described in the announcement date 29 September 2022. The Subscription and Debt Financing remain conditional on Admission.

Admission

An application has been made for 35,000,000 New Ordinary Shares to be admitted to trading on AIM. Admission of the New Ordinary Shares are expected to occur at 8.00 a.m. on, or around, 19 October 2022. The New Ordinary Shares will rank pari passu with the Existing Ordinary Shares.

Total Voting Rights

Following Admission of the New Ordinary Shares, the Company's issued ordinary share capital will consist of 679,104,621 Ordinary Shares, carrying one vote each. The Company does not currently hold any shares in treasury. Therefore, the total number of voting rights in the Company following Admission will be 679,104,621. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company, under the FCA's Disclosure Guidance and Transparency Rules.

Save as defined herein, capitalised terms have the same meaning as in the Company's Subscription and Debt Financing announcement made by the Company on 29 September 2022.

- ENDS -

[raleigh43] 10/10/2022 13:34

Well it must be 'soon' then!

[jimmyloser] 10/10/2022 09:28

If it really was 'imminent' then it must surely be 'imminent?

[raleigh43] 06/10/2022 13:14

I bought more. Will keep adding.

[amishp67] 05/10/2022 03:27

Its great to see people panic over some renovation news..gives me another chance to buy at a lower price ?

[jimmyloser] 04/10/2022 09:07

overdone on nickel and dime trades - I have bought again - short term blip impo

[richsawko] 04/10/2022 08:54

So disappointing, again!!!

[jimmyloser] 04/10/2022 08:42

I am lost for words this morning!

[genises] 04/10/2022 08:36

shame knowing this the company had not increased capacity to off set no production and therefor the share price would not drop

[red army] 04/10/2022 08:36

I hope they made enough stock to see them over this unproductive period in order to keep customers happy.

[wizzkid211] 04/10/2022 07:05

Allergy Therapeutics PLC UK manufacturing update
04/10/2022 7:00am
UK Regulatory (RNS & others)

Allergy Therapeutics (LSE:AGY)
Intraday Stock Chart

Tuesday 4 October 2022

Click Here for more Allergy Therapeutics Charts.
TIDMAGY

RNS Number : 6381B

Allergy Therapeutics PLC

04 October 2022

Allergy Therapeutics plc

("Allergy Therapeutics", "ATL" or the "Group")

Allergy Therapeutics proactively initiates a short-term pause in UK manufacturing to optimise quality systems and accelerate capacity improvements

04 October 2022 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergen immunotherapy, today announces that it has proactively paused production at the Freeman facility, part of its Worthing, UK manufacturing site, in order to accelerate ongoing site improvements. No areas for improvement are related to the safety of products and all of the Group's clinical trials remain unaffected.

The partial pause in production follows an internal review of current operating processes and is part of the Group's previously communicated ongoing programme to improve the robustness of its quality systems and build capacity across its manufacturing facilities.

Work is ongoing to minimise the commercial impact. We currently believe the pause in production will be confined to a number of weeks and we are working to limit the impact on revenue in that period.

Manuel Llobet, CEO at Allergy Therapeutics , stated: "This temporary pausing of production is a necessary step to ensure that we can both continue to deliver the highest standards of quality in our products and build capacity for the future growth of the Group. It does not affect the safety of our products. Our work to deliver ongoing improvements has identified a number of systems that require further optimisation. Accelerating this work will ensure Allergy Therapeutics is fit for the future across its growing portfolio.

"We continue to support our strong R&D driven pipeline. Our clinical trials remain on track and are completely unaffected by these manufacturing improvements."

This announcement contains inside information for the purposes of Article 7 of Regulatory (EU) No596/2014.

- ENDS -

[jimmyloser] 30/9/2022 08:00

imminently
[ im-uh-nuhnt-lee ]
adverb
very soon; at any moment:

[jimmyloser] 29/9/2022 21:13

and it wasn't that long ago they were talking of the Chinese market.

We did well today considering the cataclysmic state of the market.

[raleigh43] 29/9/2022 20:10

Lots of talk of the US market. What about the EU market?

[raleigh43] 29/9/2022 20:09

Very confident looking.

[macc1] 29/9/2022 10:39

here's an update from the management:

hxxps://youtu.be/0kD8dwzf7GM

[wizzkid211] 29/9/2022 07:12

The third pillar of the strategy, entry into the US market, moves closer, with the upcoming pivotal Phase III Grass MATA MPL trial. The total US allergy immunotherapy market is estimated to be worth $2bn with around 25% of the patients suffering from grass allergy. This indicates potential peak sales for Grass MATA MPL of approximately $300 to $400m per annum.

[wizzkid211] 29/9/2022 07:04

Allergy Therapeutics PLC Unaudited Preliminary Results 2022
29/09/2022 7:00am
UK Regulatory (RNS & others)

Allergy Therapeutics (LSE:AGY)
Intraday Stock Chart

Thursday 29 September 2022

Click Here for more Allergy Therapeutics Charts.
TIDMAGY

RNS Number : 0796B

Allergy Therapeutics PLC

29 September 2022

Allergy Therapeutics plc

("Allergy Therapeutics", "ATL" or the "Group")

Unaudited Preliminary Results for the Year ended 30 June 2022

- Phase I VLP Peanut PROTECT trial, incorporating ground-breaking VLP technology, commencing shortly

- Highly successful exploratory field trial for Grass MATA MPL, achieved 40% improvement in combined symptom and medication score compared to placebo, with pivotal Phase III trial on track to start in Q4 2022

- Robust 2022 trading with revenue of GBP72.8m (2021: GBP84.3m) on streamlined portfolio
- Continued growth of key commercial products, Pollinex, Venomil and Acarovac
29 September 2022 Allergy Therapeutics (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announces its unaudited preliminary results for the year ended 30 June 2022.

Highlights (including post-period events)

Financial

- Robust sales of GBP72.8m (2021: GBP84.3m) from commercial portfolio. Strategic streamlining of older products to focus on high value growth products has resulted in a decrease of 14% in actual terms (9%* in constant terms)

- Operating profit pre-R&D of GBP3.4m (2021: GBP16.9m) reflecting portfolio streamlining, COVID-19 headwinds and investment in supply chain

- Strong cash balance of GBP20.5m (2021: GBP40.3m) providing ongoing support for the Group's two key clinical trials

- Full year net loss of GBP13.8m (2021: Net profit of GBP2.9m)
- Announced the fundraise today for GBP7m (before expenses) and loan notes to the value of GBP10m to complete funding of October's Phase I VLP Peanut PROTECT trial, Phase III Grass MATA MPL trial as well as preparations for use of placebo arm of Grass MATA MPL trial to increase safety database and Phase II development of VLP Peanut. Fundraise supported by a number of the Company's largest shareholders.

Operational

- Acceptance by the US FDA of IND application for VLP Peanut with Phase I PROTECT trial in the US due to commence shortly

- Highly successful exploratory field trial for Grass MATA MPL, achieving 40% improvement in combined symptom and medication score compared to placebo

- Continued growth of key commercial products, Pollinex, Venomil and Acarovac, in streamlined portfolio

Manuel Llobet, CEO of Allergy Therapeutics, stated:

"Over the past financial year, we have made significant progress in advancing our clinical pipeline and we are excited to be approaching the start of two key clinical trials in our innovative immunotherapy pipeline. The first-in-human PROTECT trial of our peanut allergy vaccine candidate and the pivotal phase III trial for our grass pollen immunotherapy are significant milestones in our journey to bring these potentially life-changing treatments to patients.

"While market conditions remain challenging for many companies, our leading core European commercial business has been resilient. With a solid cash position and strong, established commercial capabilities that set us apart from solely R&D focused health companies, we are uniquely positioned to create value for our shareholders ."

*Constant currency uses prior year weighted average exchange rates to translate current year foreign currency denominated revenue to give a year-on-year comparison excluding the effects of foreign exchange movements. See table in finance review for an analysis of revenue.

This announcement contains inside information for the purposes of Article 7 of Regulatory (EU) No596/2014.

-S -

Analyst briefing and webcast today

Manuel Llobet, Chief Executive Officer, Nick Wykeman, Chief Financial Officer, and Alan Bullimore, Head of Business Innovation, will host a meeting and webcast for analysts and investors at 12pm UK time today. The live webcast can be accessed here . Please contact Consilium Strategic Communications for more details on [e-mail] .

For further information, please contact:

Allergy Therapeutics

[jimmyloser] 28/9/2022 15:47

Jimmyloser steps where angels fear to tread.

How unfortunate to have to release your results into this witches cauldron!